臨床泌尿器科70巻6号

2016年05月発行

特集 前立腺肥大症の薬物療法─使い分けのポイント

〈第一選択薬〉

PDE5阻害薬

著者： 橘田岳也¹ 篠原信雄¹

所属機関： ¹北海道大学病院泌尿器科

ページ範囲：P.404 - P.410

文献概要

▶ポイント

・前立腺肥大症に対してPDE5阻害薬は第一選択となりうる作用をもち，過去の標準的な治療薬とは異なる薬剤プロファイルをもつ．

・近い将来，PDE5阻害薬とα₁遮断薬や5α還元酵素阻害薬との併用療法は治療戦略の中心になる可能性がある．

・PDE5阻害薬の長期効果，高齢者に対する作用，薬剤のさまざまなプロファイルから導かれる効能に関するデータの蓄積は，今後の課題である．

参考文献

1） Takeda M, Nishizawa O, Imaoka T, et al : Tadalafil for the treatment of lower urinary tract symptoms in japanese men with benign prostatic hyperplasia : results from a 12-week placebo-controlled dose-finding study with a 42-week open-label extension. Low Urin Tract Symptoms 4 : 110─119, 2012

2） Yokoyama O, Yoshida M, Kim SC, et al : Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 20 : 193─201, 2013

3） Takeda M, Yokoyama O, Lee SW, et al : Tadalafil 5mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol 21 : 670─675, 2014

4） https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

5） 日本泌尿器科学会 （編） : 前立腺肥大症診療ガイドライン. リッチヒルメディカル, 東京, 2011

6） Kloner RA, Hutter AM, Emmick JT, et al : Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 42 : 1855─1860, 2003

7） Yokoyama O, Igawa Y, Takeda M, et al : Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia : a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol 7 : 249─264, 2015

8） Regadas RP, Reges R, Cerqueira JB, et al : Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia : a randomized, placebo-controlled clinical trial. Int Urol Nephrol 45 : 39─43, 2013

9） Goldfischer E, Kowalczyk JJ, Clark WR, et al : Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy : results of a multicenter randomized, double-blind, placebo-controlled trial. Urology 79 : 875─882, 2012

10） Gacci M, Corona G, Salvi M, et al : A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61 : 994─1003, 2012

11） Casabe A, Roehrborn CG, Da Pozzo LF, et al : Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191 : 727─733, 2014

12） Park HJ and Park NC : Combination therapy with dutasteride and tadalafil in men with moderate to severe benign prostatic hyperplasia. Eur Urol 12 （Supple） : e1092, 2013

13） Porst H, Oelke M, Goldfischer ER, et al : Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia : subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 82 : 667─673, 2013

14） Oelke M, Giuliano F, Baygani SK, et al : Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms （LUTS） suggestive of benign prostatic hyperplasia （BPH） : results from a randomised, placebo-controlled study. BJU Int 114 : 568─575, 2014

15） Tsai BM, Turrentine MW, Sheridan BC, et al : Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 81 : 272─278, 2006

16） Roumeguere T, Zouaoui Boudjeltia K, Babar S, et al : Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha. Eur Urol 57 : 522─528, 2010

17） Garcia-Barroso C, Ricobaraza A, Pascual-Lucas M, et al : Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64 : 114─123, 2013

18） Oelke M, Becher K, Castro-Diaz D, et al : Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons : results of a systematic literature review and international consensus validation process （LUTS-FORTA 2014）. Age Ageing 44 : 745─755, 2015